Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 8/20 | 0.53 |
| ▸ | ERAP2 | Q6P179 | 6/20 | 0.46 |
| ▸ | ERAP1 | Q9NZ08 | 5/20 | 0.46 |
| ▸ | LNPEP | Q9UIQ6 | 5/20 | 0.46 |
| ▸ | IL1RN | P18510 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | CTSC | P53634 | 2/20 | 0.44 |
| ▸ | GHSR | Q92847 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4676538 | 1.00 | KISS1R (0.53) | KISS1RERAP2ERAP1LNPEPIL1RN | |
| SCHEMBL4680626 | 0.87 | FCER2 (0.51) | KISS1RERAP2ERAP1LNPEPACE | |
| SCHEMBL4682112 | 0.87 | FCER2 (0.51) | KISS1RERAP2ERAP1LNPEPACE | |
| SCHEMBL4675732 | 0.85 | KISS1R (0.49) | KISS1RERAP2ERAP1LNPEPIL1RN | |
| SCHEMBL4676548 | 0.85 | KISS1R (0.49) | KISS1RERAP2ERAP1LNPEPIL1RN | |
| SCHEMBL4675968 | 0.84 | KISS1R (0.48) | KISS1RERAP2ERAP1LNPEPACE | |
| SCHEMBL4676002 | 0.84 | KISS1R (0.48) | KISS1RERAP2ERAP1LNPEPACE | |
| SCHEMBL4677816 | 0.82 | KISS1R (0.53) | KISS1RERAP2ERAP1LNPEPIL1RN | |
| SCHEMBL4682122 | 0.82 | KISS1R (0.53) | KISS1RERAP2ERAP1LNPEPIL1RN | |
| SCHEMBL4677507 | 0.82 | KISS1R (0.43) | KISS1RCTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633702-B1 | PROTEASE INHIBITORS | PROZYMEX AS (DK) | 2008-07-02 | — | — | EP | claimed |
| US-20070155803-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-07-05 | — | — | US | claimed |
| EP-1975153-A2 | Protease inhibitors | Prozymex A/S (DK) | 2008-10-01 | — | — | EP | disclosed |
| EP-1975153-A2 | Protease inhibitors | Prozymex A/S (DK) | 2008-10-01 | — | — | EP | disclosed |
| EP-1633702-B1 | PROTEASE INHIBITORS | PROZYMEX AS (DK) | 2008-07-02 | — | — | EP | disclosed |
| EP-1633702-B1 | PROTEASE INHIBITORS | PROZYMEX AS (DK) | 2008-07-02 | — | — | EP | disclosed |
| US-20070155803-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-07-05 | — | — | US | disclosed |
| US-20070155803-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-07-05 | — | — | US | disclosed |
| US-20070155803-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-07-05 | — | — | US | disclosed |
| WO-2004106289-A1 | PROTEASE INHIBITORS | PROZYMEX A/S (DK) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155803-A1 | Protease inhibitors | DPP7, DPP9, DPP3 | KISS1R 1337/4885ERAP2 360/4885ERAP1 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.